ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 17384684

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Tomlinson DC and 2 others. Oncogene, 2007. Cited by 110 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Papers, record 17384684. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17384684

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
PubMed
Journal
Oncogene
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
110
iCite
Relative citation ratio, by iCite
2.16
iCite
Revised in PubMed
2025-05-29
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tomlinson DCD C
2Hurst CDC D
3Knowles MAM A

Source PubMed

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
Gene Expression Regulation, NeoplasticMajor topic
MutationMajor topic
RNAMajor topic
Receptor, Fibroblast Growth Factor, Type 3Major topic
Urinary Bladder NeoplasmsMajor topic
Cell Line, Tumor
Dimerization
Gene Transfer Techniques
Genetic Therapy
Humans
Phenotype
Phosphorylation
Protein Isoforms
Retroviridae

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
A5433Cancer Research UKUnited KingdomPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110,918,587Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.Oncogene2000https://conductscience.org/library/papers/10918587PubMed
216,619,045Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.Oncogene2006https://conductscience.org/library/papers/16619045PubMed
311,066,086Redefining a critical region of LOH on 4p16.3 in bladder cancer.Genes Chromosomes Cancer2000https://conductscience.org/library/papers/11066086PubMed
411,157,491Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.Blood2001https://conductscience.org/library/papers/11157491PubMed
511,245,416The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.Cancer Res2001https://conductscience.org/library/papers/11245416PubMed
611,294,897Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.Mol Biol Cell2001https://conductscience.org/library/papers/11294897PubMed
711,395,371Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.Am J Pathol2001https://conductscience.org/library/papers/11395371PubMed
811,429,702Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.Oncogene2001https://conductscience.org/library/papers/11429702PubMed
911,529,856Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).Br J Haematol2001https://conductscience.org/library/papers/11529856PubMed
1011,745,189The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.Cancer2001https://conductscience.org/library/papers/11745189PubMed

1 to 10 of 51

See all 51 references

Cited by65

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 110 citations.

PMIDTitleJournalYearIn PapersSource
42,633,326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326PubMed
41,310,273Towards biomarker-driven therapies for urothelial carcinoma.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/41310273PubMed
40,418,326FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients.Virchows Arch2025https://conductscience.org/library/papers/40418326PubMed
39,468,056Chemoproteogenomic stratification of the missense variant cysteinome.Nat Commun2024https://conductscience.org/library/papers/39468056PubMed
39,161,208FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Cancer Commun (Lond)2024https://conductscience.org/library/papers/39161208PubMed
39,138,146Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39138146PubMed
39,031,286The roles of FGFR3 and c-MYC in urothelial bladder cancer.Discov Oncol2024https://conductscience.org/library/papers/39031286PubMed
38,255,923Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers.Int J Mol Sci2024https://conductscience.org/library/papers/38255923PubMed
38,175,774Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.Cancer Res2024https://conductscience.org/library/papers/38175774PubMed
37,305,616Significance of the FGFR3 mutation in Chinese patients with bladder cancer.Transl Androl Urol2023https://conductscience.org/library/papers/37305616PubMed

1 to 10 of 65

See all 65 cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
EGF1,950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
FGF12,246PubTator's text mininghttps://conductscience.org/library/genes/2246NCBI Gene
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
IGH3,492PubTator's text mininghttps://conductscience.org/library/genes/3492NCBI Gene
RET5,979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene
SDHA6,389PubTator's text mininghttps://conductscience.org/library/genes/6389NCBI Gene
TERT7,015PubTator's text mininghttps://conductscience.org/library/genes/7015NCBI Gene
TP537,157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

1 to 10 of 11

See all 11 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17384684

GET https://conductscience.org/api/papers/v1/17384684/references?page=2

API referenceFor AI assistants